Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 10/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530417 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APDE4APDE4B | |
| SCHEMBL2526734 | 0.98 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2APDE4APDE4B | |
| SCHEMBL2532749 | 0.86 | PDE4B (0.50) | ALDH1A1MEN1KMT2APDE4APDE4B | |
| SCHEMBL2527662 | 0.81 | PDE4B (0.56) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2531912 | 0.81 | PDE4B (0.56) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2526209 | 0.81 | PDE4B (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2528821 | 0.77 | PDE4B (0.58) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2531840 | 0.77 | PDE4B (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22163586 | 0.77 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL608156 | 0.76 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011768-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011768-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011768-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, CD68 | ALDH1A1 3761/4885MEN1 3737/4885KMT2A 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.